CTLA4 and cancer: Since the publication of the results of the pivotal ipilimumab trial for metastatic melanoma in 2010, there has been significant development in immunotherapy, especially in relation to blockers of immune checkpoints, including CTLA-4, PD-1, and PD-L1, which have a durable beneficial effect in a proportion of cancer patients.